The French diagnostic test company bioMérieux (Euronext: BIM) will establish a joint venture in Shanghai with Shanghai Kehua Bio-engineering. The JV will assume production of bioMérieux’s diagnostic test kits. bioMérieux announced in late 2007 that it would gradually shutter its Boxtel plant in the Netherlands, where the kits are currently produced. Production of its microplate immunoassay line will moved to the new Shanghai JV, which will be 60% owned by bioMérieux. The immunoassays will be distributed world-wide. More details...

Stock Symbols: (Euronext: BIM) (SHE: 002022)